Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Gilead Sciences, Inc. specializes in the development and commercialization of innovative antiviral drugs, particularly for HIV, hepatitis B, hepatitis C, and influenza. Its competitive position is bolstered by a robust pipeline of therapies, including the recently approved CAR-T therapy for certain cancers, and a strong global presence, particularly in the U.S. and Europe.
Gilead generates revenue primarily through the sale of its patented antiviral medications, leveraging strong pricing power due to the high demand for its innovative therapies. The company benefits from economies of scale in production and distribution, allowing it to maintain competitive pricing while maximizing margins.
FDA approvals for new drugs or indications, particularly in oncology and HIV
Sales performance of key products like Biktarvy and Harvoni
Pipeline developments and clinical trial results
Market share changes in the antiviral space
Regulatory changes affecting drug pricing and approval processes
Technological disruption in drug development methodologies
Emergence of generic competitors for key products
Innovative therapies from biotech firms that could capture market share
Potential for increased debt levels if acquisitions are pursued aggressively
Liquidity risks if cash flows are impacted by market dynamics
moderate - Gilead's performance is somewhat tied to healthcare spending trends, which can be influenced by economic cycles.
Interest rates can affect Gilead's cost of capital for R&D investments, but the company is less sensitive to consumer demand fluctuations due to its focus on essential medications.
minimal - Gilead has a strong balance sheet with low debt levels, reducing its exposure to credit market fluctuations.
growth - Gilead's innovative pipeline and strong market position attract growth-focused investors.
moderate - historical volatility is influenced by regulatory news and clinical trial outcomes.
